<?php
/**
 * Forum topic creation stub — Enicepatide
 * Generated: 2026-11-04
 * To apply: execute via WP-CLI or SSH once forum access is available
 *   wp eval-file forum_pending/20261104_enicepatide.php
 */

$topic_data = [
    'title'   => 'New Research Thread: Enicepatide (CT-388) — Roche\'s Dual GLP-1/GIP Agonist, 22.5% Weight Loss Phase 2, Phase 3 ENITH Underway',
    'content' => '<p><strong>Compound:</strong> Enicepatide (CT-388, RO7795068)<br>'
               . '<strong>Class:</strong> Dual GLP-1 / GIP receptor agonist<br>'
               . '<strong>Developer:</strong> Roche / Genentech<br>'
               . '<strong>Dosing:</strong> Once-weekly subcutaneous injection (Phase 2: up to 24 mg)</p>'
               . '<p><strong>Key Phase 2 Results:</strong><br>'
               . '<em>CT-388-103 (Obesity, 48 weeks, N=469):</em><br>'
               . '• Placebo-adjusted weight loss: −22.5% (efficacy estimand) or −18.3% (treatment-regimen estimand) at 24 mg<br>'
               . '• Weight trajectory not plateaued at week 48<br><br>'
               . '<em>CT-388-104 (Type 2 Diabetes, 48 weeks, N=447 — topline September 22, 2026):</em><br>'
               . '• Body weight: approximately −15.5%<br>'
               . '• HbA1c: −2.65 percentage points from baseline of 8.1%<br>'
               . '• AE discontinuation: 2.0% vs 0.0% placebo</p>'
               . '<p><strong>Phase 3:</strong> ENITH program, 2 obesity trials initiated 2026. Roche is also planning a combination trial with petrelintide (amylin analog) for additive weight-loss efficacy.</p>'
               . '<p><strong>Discussion starters:</strong><br>'
               . '1. The 22.5% efficacy-estimand figure is striking — but how does the 18.3% treatment-regimen figure compare to what we\'ve seen from tirzepatide?<br>'
               . '2. Roche is planning to combine enicepatide + petrelintide (GLP-1/GIP + amylin simultaneously) — is a triple-mechanism approach the future of obesity treatment?<br>'
               . '3. What are your thoughts on the 2.65% HbA1c reduction for T2D patients — does this compete with established standards of care?</p>'
               . '<p><a href="https://minmaxmuscle.com/peptides/enicepatide">Full research dossier on MinMaxMuscle →</a></p>'
               . '<p><em>Research compounds discussed for educational purposes only. Not approved for human use. Consult a healthcare provider.</em></p>',
    'forum'   => 'peptide-research',
    'author'  => 'minmaxmuscle_admin',
];

echo "=== Forum Topic to Create ===\n";
echo "Title: " . $topic_data['title'] . "\n";
echo "Forum: " . $topic_data['forum'] . "\n";
echo "Content length: " . strlen($topic_data['content']) . " chars\n";
echo "\nTo post via REST (replace TOKEN):\n";
echo 'curl -X POST https://blog.minmaxmuscle.com/wp-json/asgaros-forum/v1/topics \\' . "\n";
echo '  -H "Authorization: Basic <BASE64_WP_CREDENTIALS>" \\' . "\n";
echo '  -H "Content-Type: application/json" \\' . "\n";
echo "  -d '" . json_encode($topic_data, JSON_PRETTY_PRINT) . "'\n";
